amit agarwal

Assistant Prof. Neurology, Amrita institute of medical sciences, Faridabad• Post doctoral fellow in Epilepsy• DM Neurology • AIIMS, New Delhi ALUMNUS•

[Neurology Journal @GreenJournal]

Learn more with this Teaching Video NeuroImage case: https://t.co/P0JKJhYszB

[NEJM @NEJM]

Original Article: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF trial) https://t.co/fsN8QZhgYh

Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke https://t.co/RX8U46dRZb

#Cardiology #ESCCongress

[Frontiers - Neurology @FrontNeurol]

New Research: Relationship between atypical language lateralization and cognition in pediatric patients with drug-resistant focal epilepsy: role of working memory https://t.co/rbHWqrCZAp #FrontiersIn #Neurology

[Frontiers - Neurology @FrontNeurol]

New Research: Efficacy, treatment retention, and tolerability of newer- versus older-generation antiseizure medications in older adults with epilepsy: a systematic review and meta-analysis https://t.co/GtVGECNQYU #FrontiersIn #Neurology

[The Lancet @TheLancet]

🏷️ @AlSerranoPozo @MassGenBrigham @ADRCMass @ValentinaEPrice @grinberg_t @TharickAPascoal @PittTweet @UPMCnews @M_SuarezCalvet

[Neurology Journal @GreenJournal]

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society https://t.co/ycnKgZBldQ

[Neurology Today @NeurologyToday]

A new study of anti-IgLON5 disease has brought into focus the need for neurologists to consider it in their differential diagnoses: https://t.co/sXB3ePhxc9

#NeuroTwitter #autoimmune @AlbertoEspay @idibaps

[Journal of Neurology, Neurosurgery and Psychiatry @JNNP_BMJ]

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
https://t.co/JG7ZN4PLbE

[Frontiers - Neurology @FrontNeurol]

New Research: Non-invasive neuromodulation for drug-resistant epilepsy: a contemporary structured review of mechanisms, clinical evidence and future directions https://t.co/5VH3SE8cv7 #FrontiersIn #Neurology

[Neurology: Clinical Practice @NeurologyCP]

Characterizing Onset Limit and Surgical Outcome Factors in Type II Focal Cortical Dysplasia-Related Epilepsy https://t.co/XNMQ6WQbjj

[Neurology Journal @GreenJournal]

This study assessed long-term outcomes in autoimmune encephalitis. Read more: https://t.co/e84kPkw3NT

[NEJM @NEJM]

Inflammatory myopathies are typically associated with a myositis-specific autoantibody that determines the diagnosis and prognosis. Myositis subgroups have distinct pathomechanisms that now allow for targeted therapies.

Learn more in the Review Article “Inflammatory Myopathies” by Yves Allenbach, MD, PhD, and Olivier Benveniste, MD, PhD: https://t.co/ZeCKdNe87v

[JAMA Neurology @JAMANeuro]

From JAMA: Amyotrophic lateral sclerosis (#ALS) is an adult-onset neurodegenerative disorder characterized by progressive muscle weakness due to degeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord.

https://t.co/VvFlo5RKbX

[Nat Rev Neurology @NatRevNeurol]

New online! Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system https://t.co/AP83Zlnxy6

[Epileptic Disorders @EpiDisorders]

Neonatal seizures ≠ always what they seem! ⚡ Video-EEG + EMG can spot vitamin-dependent epilepsy early, guiding treatment before genetics confirm it. Look for erratic myoclonus + epileptic spasms.

https://t.co/NPKcSejyPq

[Case Western Reserve Univ/UH Epilepsy Program @CwruEpilepsy]

📢PUBLICATION ALERT Congratulations to our former fellow & current @CwruNeuro resident @Saeidehslz1368 for first publication in @JClinNeurophys
https://t.co/ZVLgwoHRvf
#NeuroX #Epilepsy #SeizureSemiology #EEG
@neelmed

[Marcus Pinto, MD, MS @MarcusVPinto]

IVIg for CIDP: Start with the loading dose (2 g/kg), then give 1 g/kg every 3 weeks. Schedule a follow-up visit in 9-12 weeks. Treatment response should be assessed using the INCAT score (at least 1 point improvement) and/or the MRC sum score (>2 points). If there is no response, reconsider the diagnosis, as it is unlikely to be CIDP. Do not use symptom improvement or “halted progression” as proof of response. Refer to a @gbscidp center of excellence if there is no response or if there are doubts about the diagnosis.

[JAMA @JAMA_current]

Restless legs syndrome (RLS), a sleep-related movement disorder, is present in approximately 3% of adults worldwide.

📄 This Review summarizes the pathophysiology, epidemiology, risk factors, diagnosis, treatment, and prognosis of #RestlessLegsSyndrome.

https://t.co/YG7PBP9ujL

[Andrew Micieli @MicieliA_MD]

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5).

https://t.co/kewnzm8pKp